Posted by Michael Wonder on 19 May 2021
Pfizer withdraws evidence submission for Staquis
19 May 2021 - NICE is unable to make a recommendation on the use of crisaborole for the treatment of people 2 years and older with mild to moderate atopic dermatitis.
NICE is unable to make a recommendation on the use of crisaborole on the NHS because Pfizer withdrew its evidence submission.
Pfizer has confirmed that it does not wish to make an evidence submission for the appraisal because currently the technology will not be launched in the UK.
